ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Neuroscience

Neurocrine buys into Voyager gene therapies

by Lisa M. Jarvis
February 1, 2019 | APPEARED IN VOLUME 97, ISSUE 5

 

Neurocrine Biosciences has bought into Voyager Therapeutics’ gene-therapy programs for Parkinson’s disease and Friedreich’s ataxia. Neurocrine will pay Voyager $115 million up front and take a stake worth $50 million in the biotech firm. It will also fund the late-stage study of the Parkinson’s gene therapy, which delivers into neurons the gene for the enzyme that converts levodopa into dopamine. For both programs, Voyager can opt in to comarket the drug in the US after certain clinical data are revealed.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment